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doi:10.1016/j.jtcvs.2006.10.029ore than a decade ago, the concept of cell replacement therapy to treat
heart failure was born.1 The initial framework proposed that if congestive
heart failure is caused by the loss of contractile units in the heart, then
eplacement of contractile units should reverse heart failure. Initially, fetal cardio-
yocytes were used, but the implanted cells did not beat with the rest of the
ardiomyocytes, and the cells remained functionally isolated. Other muscle cell
ypes, including skeletal myoblasts and smooth muscle cells, also failed to adopt a
ontractile phenotype. The implantation of these noncontractile units, however, was
hown to improve cardiac function. It was argued that the implantation of autolo-
ous contractile units would improve cardiac function above and beyond that
ccomplished with noncontractile cells, and the search began to shift from commit-
ed muscle cells to noncommitted stem cells that could potentially be induced to
ecome cardiomyocyte like.
A flurry of activity ensued, and in the rush to discover this new landscape, one
s left with the impression that a few tumbled. Although a handful of groups focused
n the embryonic stem cells, the majority turned to an autologous source of stem
ells to avoid the ethical quagmire that accompanies the use of embryonic stem cells
or therapeutic purposes. Scientists knew the bone marrow stem cells well. Reports
merged that hematopoietic stem cells could transdifferentiate into cardiomyocytes.
his was convenient because the bone marrow is easy to aspirate, and the stem cells
re easy to purify with our currently available technology. On the basis of two
eports in mice,2,3 clinical trials were organized and carried out with feverish
ctivity across the globe.4 Various bone marrow cell preparations were infused or
njected into the heart. Some observers might have been heard in the background
hispering primum non nocere because the biology of bone marrow cell implan-
ation into injured myocardium had not been rigorously examined.
Amid this surge of activity, three reports simultaneously emerged that demon-
trated that hematopoietic stem cells do what hematopoietic stem cells are supposed
o do and no more; even when injected into the heart they give rise to hematopoietic
rogeny and not to cardiomyocytes.5-7 Few implored the field to re-examine the
ationale that guided the design of clinical trials of bone marrow cell therapy.8
In retrospect, there existed neither biological precedence nor teleological justi-
cation for expecting the hematopoietic stem cells to overachieve above and beyond
heir known biology and to transdifferentiate to cardiomyocytes. However, observ-
rs pointed out that even in the absence of any sort of transdifferentiation, infusion
r implantation of the stem cells still appeared to improve cardiac function in the
ouse model.5 Therefore the improvement in cardiac function must be independent
f the transdifferentiation of the cells to cardiomyocytes; that is, the cells might have
nforeseen beneficial effects that we clearly do not understand. If the cells do not
ransdifferentiate, they probably achieve their benefit through paracrine elaboration
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Lf factors,9 but this aspect of the biology of cell implanta-
ion is poorly understood. In other words, there is still no
iological rationale for trials of bone marrow cell therapy
or ischemic heart disease, at least as we stand today.
The present article is by one of the first groups of
nvestigators that set out on the clinical path to evaluate the
fficacy of cell transplantation into the ischemic cardiomyo-
athic heart at the time of coronary artery bypass grafting
CABG).10 I congratulate them for having persevered with
he current trial, which is a natural continuation of the
revious one.
The authors chose AC133-expressing CD34 bright bone
arrow endothelial progenitor cells, which is a relatively pure
opulation. This subpopulation of cells, however, also includes
he progenitor cells for granulocytes, macrophages, and possi-
ly erythrocytes.11 Certainly basic science data convincingly
uggest that this cell population could be quite beneficial in
nducing angiogenesis in ischemic tissue. The wide range of
ell doses (1.280  106 cells) that were implanted into the
atients makes it difficult to interpret some of the safety and
fficacy data. On the basis of the mouse data, in which ap-
roximately 1 105 cells were implanted, the weight-adjusted
ell dose for human subjects should probably be closer to the
igher cell dose that Stamm and colleagues10 used.
The authors included patients with a previous myocardial
nfarction. Initially, all patients had distinct areas of akinesis
hat corresponded to the region of infarction. It would have
een valuable if the viability within these akinetic regions was
lso evaluated. A viable but akinetic segment is anticipated to
esume function after adequate blood flow is restored with
ABG. A nonviable and akinetic scar is unlikely to derive
enefit from CABG alone. Also, the effect of the cells might be
ntirely different when transplanted in viable versus nonviable
cars. In the former the cells might restore function by inducing
ngiogenesis. In the latter the effect of the cells on the matrix
ithin the scar is likely to be far more important than the effect
f the cells on angiogenesis. I would agree with the first
nclusion criteria that excluded patients with global dysfunc-
ion. One of the other patient variables, which I recognize is
ifficult to control, is whether the diseased artery supplying the
kinetic area is grafted. It appears as though the authors con-
tructed a bypass in some cases in which it was feasible but not
n others when the artery was not bypassable. Although this is
reflection of real life, it makes the interpretation of the
fficacy data more difficult.
The authors began their trial with an appropriate 1:1 ran-
omization protocol. I share the authors’ frustration in having
o give up the randomization scheme because of logistic issues.
n addition, the issue of appropriate control subjects will con-
inue to be a difficult one in this field because bone marrow
spiration in the CABG-only group is quite invasive, but if
one marrow aspiration is not done, it would unblind the
atient and the caregiver to the treatment received. Perhaps the
00 The Journal of Thoracic and Cardiovascular Surgery ● Marcatients should undergo a sham bone marrow aspiration to
inimize the placebo effect. Also, the CABG-only group
hould receive equivalent needle punctures into the akinetic
egments to further limit variation between the groups.
As this study confirms, the cell injection appears to be
afe. Concerns regarding induction of arrhythmias exist
ith cell therapy, and I think all patients should have
ppropriate monitoring, safety devices available, or both.
mplantation of an internal defibrillator would satisfy both
riteria but is invasive. Short-term telemetry does not cap-
ure late arrhythmias, but induction of arrhythmia probably
as a high early hazard ratio.
It is encouraging that the implantation of the cells im-
roved the ejection fraction by 6.3%, but interpretation of
his datum should be made within the context of some of the
bove issues. I agree with the author’s conclusion that larger
andomized and controlled studies are clearly warranted. I
hink the future trials should include a homogenous group of
atients with clear delineation of viable versus nonviable
yocardium and use a narrow cell dose and, most impor-
antly, should be performed in a blinded, randomized, and
ontrolled setting. A few good men and women are wanted
o perform such a study. Dr Christof Stamm and colleagues
ertainly appear to be in a unique position to continue to
ush to ripen this field.
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